SID 2026Abstract 0517
Zumilokibart (APG777), a half-life-extended monoclonal antibody, provides rapid and sustained inhibition of type 2 biomarkers in moderate-to-severe atopic dermatitis
Guttman-Yassky E, Gooderham M, Silverberg J, Blauvelt A, Thankamony S, Nograles K, Dambkowski C, Dillinger L, Kabashima K
SID Annual Meeting 2026Chicago, 13–16 May 2026 · published in JID 21 Jul 2026
Topics: Atopic dermatitis & eczema
Abstract
The abstract’s text is on the JID website.
DOI 10.1016/j.jid.2026.06.548 · Not in PubMed: details from Crossref